Experienced in Brain Tumor

Dr. Renuka V. Iyer

Oncology
Roswell Park Cancer Institute
Elm And Carlton St, 
Buffalo, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Brain Tumor
Roswell Park Cancer Institute
Elm And Carlton St, 
Buffalo, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Renuka Iyer is an Oncologist in Buffalo, New York. Dr. Iyer is rated as an Experienced provider by MediFind in the treatment of Brain Tumor. Her top areas of expertise are Neuroendocrine Tumor, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Pancreatic Islet Cell Tumor, and Tissue Biopsy.

Her clinical research consists of co-authoring 109 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

ROSWELL PARK CANCER INSTITUTE
Elm And Carlton St, Buffalo, NY 14263

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 2/Phase 3
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Other, Procedure, Drug
Study Drug: Cabozantinib S-malate
Study Phase: Phase 3
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
A Phase 2 Study of Pevonedistat in Combination With Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Pevonedistat
Study Phase: Phase 2
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib
Study Phase: Phase 2
A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients With Metastatic Neuroendocrine Tumors (NETs)
A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients With Metastatic Neuroendocrine Tumors (NETs)
Enrollment Status: Completed
Publish Date: September 11, 2025
Intervention Type: Biological, Drug
Study Drugs: Incomplete Freund's Adjuvant, Octreotide, Sargramostim, SurVaxM Survivin Long Peptide Vaccine
Study Phase: Phase 1
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Drug
Study Drugs: Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 3
A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)
A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Pembrolizumab, Sorafenib Tosylate
Study Phase: Phase 1/Phase 2
A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers
A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Atezolizumab, Cobimetinib, Varlilumab
Study Phase: Phase 2
Phase 2 Single-Arm Study of Nanoliposomal Irinotecan With Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin
Phase 2 Single-Arm Study of Nanoliposomal Irinotecan With Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin
Enrollment Status: Terminated
Publish Date: January 30, 2025
Intervention Type: Drug, Procedure
Study Drugs: Fluorouracil, Leucovorin, Liposomal Irinotecan
Study Phase: Phase 2
A Randomized Phase II Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
A Randomized Phase II Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Enrollment Status: Terminated
Publish Date: June 05, 2024
Intervention Type: Drug, Other
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
An Expanded Access Program of Surufatinib for Patients With Advanced or Metastatic Neuroendocrine Tumors
An Expanded Access Program of Surufatinib for Patients With Advanced or Metastatic Neuroendocrine Tumors
Enrollment Status: No_longer_available
Publish Date: April 12, 2024
Intervention Type: Drug
Multicenter Phase 2 Study of Nintedanib for Patients With Advanced Carcinoid Tumors
Multicenter Phase 2 Study of Nintedanib for Patients With Advanced Carcinoid Tumors
Enrollment Status: Completed
Publish Date: December 26, 2023
Intervention Type: Other, Drug
Study Drug: Nintedanib
Study Phase: Phase 2
A Phase I Study of Ceritinib (LDK378), a Novel ALK Inhibitor, in Combination With Gemcitabine-Based Chemotherapy in Patients With Advanced Solid Tumors
A Phase I Study of Ceritinib (LDK378), a Novel ALK Inhibitor, in Combination With Gemcitabine-Based Chemotherapy in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 25, 2022
Intervention Type: Drug, Other
Study Phase: Phase 1
Granzyme B Production as a Biomarker for the Immunomodulatory Activity of Sorafenib in HCC
Granzyme B Production as a Biomarker for the Immunomodulatory Activity of Sorafenib in HCC
Enrollment Status: Completed
Publish Date: July 25, 2022
Intervention Type: Other, Drug
Study Phase: Not Applicable
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
Enrollment Status: Completed
Publish Date: December 10, 2020
Intervention Type: Drug
Study Phase: Phase 1
Multicenter Phase 1b/2 Study of Tivozanib in Patients With Advanced Inoperable Hepatocellular Carcinoma
Multicenter Phase 1b/2 Study of Tivozanib in Patients With Advanced Inoperable Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: October 28, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 16 Less Clinical Trials

109 Total Publications

Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: September 10, 2025
Similar Doctors
Advanced in Brain Tumor
Dr. Sheheryar K. Kabraji
Hematology Oncology | Oncology | Emergency Medicine
Advanced in Brain Tumor
Dr. Sheheryar K. Kabraji
Hematology Oncology | Oncology | Emergency Medicine

Roswell Park Cancer Institute

Elm And Carlton St, 
Buffalo, NY 
 (0.1 miles away)
716-845-2300
Languages Spoken:
English
See accepted insurances

Sheheryar Kabraji is a Hematologist Oncology specialist and an Oncologist in Buffalo, New York. Dr. Kabraji is rated as an Advanced provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, and Paget Disease of the Breast.

Experienced in Brain Tumor
Dr. Igor Puzanov
Hematology | Oncology
Experienced in Brain Tumor
Dr. Igor Puzanov
Hematology | Oncology

Roswell Park Cancer Institute

Elm And Carlton St, 
Buffalo, NY 
 (0.1 miles away)
716-845-2300
Languages Spoken:
English
See accepted insurances

Igor Puzanov is a Hematologist and an Oncologist in Buffalo, New York. Dr. Puzanov is rated as a Distinguished provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Melanoma, Renal Cell Carcinoma (RCC), Breast Cancer, Tissue Biopsy, and Nephrectomy.

Experienced in Brain Tumor
Dr. Neeta Soni
Oncology
Experienced in Brain Tumor
Dr. Neeta Soni
Oncology

The Memorial Hospital Of William F And Gertrude F Jones Inc

1504 W State St, 
Olean, NY 
 (62.0 miles away)
585-596-0145
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Neeta Soni is an Oncologist in Olean, New York. Dr. Soni is rated as an Advanced provider by MediFind in the treatment of Brain Tumor. Her top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Chronic Lymphocytic Leukemia (CLL), and Paget Disease of the Breast.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Iyer's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 8 Advanced Conditions
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile